JP2011509302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509302A5 JP2011509302A5 JP2010542343A JP2010542343A JP2011509302A5 JP 2011509302 A5 JP2011509302 A5 JP 2011509302A5 JP 2010542343 A JP2010542343 A JP 2010542343A JP 2010542343 A JP2010542343 A JP 2010542343A JP 2011509302 A5 JP2011509302 A5 JP 2011509302A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- hydrogen
- compound
- alkyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 139
- 229910052739 hydrogen Inorganic materials 0.000 claims description 66
- 239000001257 hydrogen Substances 0.000 claims description 66
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 51
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 6
- -1 3-fluorophenoxy Chemical group 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 230000003463 hyperproliferative effect Effects 0.000 claims description 5
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims description 4
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims description 4
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims description 4
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 24
- 0 C*(*)C*(C)C(C)(*)C(N(CCN(c1c(*)cnc2c1c(*)n[n]2)I)I)=O Chemical compound C*(*)C*(C)C(C)(*)C(N(CCN(c1c(*)cnc2c1c(*)n[n]2)I)I)=O 0.000 description 18
- 241000124008 Mammalia Species 0.000 description 4
- SRUBQVFBUPNJPS-UIOOFZCWSA-N CC(C)(CC1)N[C@@H]1[C@@H](C(N(CC1)CCN1c(c(cn[nH]1)c1nc1)c1-c1ccccc1)=O)c(cc1)ccc1Cl Chemical compound CC(C)(CC1)N[C@@H]1[C@@H](C(N(CC1)CCN1c(c(cn[nH]1)c1nc1)c1-c1ccccc1)=O)c(cc1)ccc1Cl SRUBQVFBUPNJPS-UIOOFZCWSA-N 0.000 description 1
- FKPBPDTXHICJSN-XMMPIXPASA-N CC(C)NCC[C@@H](C(N(CC1)CCN1c(c(cn[nH]1)c1nc1)c1-c1cccc(F)c1)=O)c(cc1)ccc1Cl Chemical compound CC(C)NCC[C@@H](C(N(CC1)CCN1c(c(cn[nH]1)c1nc1)c1-c1cccc(F)c1)=O)c(cc1)ccc1Cl FKPBPDTXHICJSN-XMMPIXPASA-N 0.000 description 1
- KGZLISZNHMDDIA-XMMPIXPASA-N CC(C)NC[C@@H](C(N(CC1)CCN1c(c(c(OC)n[nH]1)c1nc1)c1-c1ccccc1)=O)c(cc1)ccc1Cl Chemical compound CC(C)NC[C@@H](C(N(CC1)CCN1c(c(c(OC)n[nH]1)c1nc1)c1-c1ccccc1)=O)c(cc1)ccc1Cl KGZLISZNHMDDIA-XMMPIXPASA-N 0.000 description 1
- XSEBVQYOKBAUMZ-XMMPIXPASA-N CC(C)NC[C@@H](C(N(CC1)CCN1c(c(cn[nH]1)c1nc1)c1-c1ccccc1)=O)c(cc1)ccc1Cl Chemical compound CC(C)NC[C@@H](C(N(CC1)CCN1c(c(cn[nH]1)c1nc1)c1-c1ccccc1)=O)c(cc1)ccc1Cl XSEBVQYOKBAUMZ-XMMPIXPASA-N 0.000 description 1
- KWRPNMQGGUOVAY-LJQANCHMSA-N CC(C)NC[C@@H](C(N(CC1)CCN1c(c(cn[nH]1)c1nc1)c1C#N)=O)c(cc1)ccc1Cl Chemical compound CC(C)NC[C@@H](C(N(CC1)CCN1c(c(cn[nH]1)c1nc1)c1C#N)=O)c(cc1)ccc1Cl KWRPNMQGGUOVAY-LJQANCHMSA-N 0.000 description 1
- KCGMPJYIKCDNNU-QGZVFWFLSA-N CC(C)NC[C@@H](C(N(CC1)CCN1c1c(C(F)(F)F)cnc2c1cn[nH]2)=O)c(cc1)ccc1Cl Chemical compound CC(C)NC[C@@H](C(N(CC1)CCN1c1c(C(F)(F)F)cnc2c1cn[nH]2)=O)c(cc1)ccc1Cl KCGMPJYIKCDNNU-QGZVFWFLSA-N 0.000 description 1
- VFQMWGVFLLUWME-GFOWMXPYSA-N CC(C)NC[C@@H](C(N(CC1)CCN1c1ccnc2c1c(OCC(CO)O)n[nH]2)=O)c(cc1)ccc1Cl Chemical compound CC(C)NC[C@@H](C(N(CC1)CCN1c1ccnc2c1c(OCC(CO)O)n[nH]2)=O)c(cc1)ccc1Cl VFQMWGVFLLUWME-GFOWMXPYSA-N 0.000 description 1
- HUYJXXMOMIZURM-LJQANCHMSA-N CC(C)NC[C@@H](C(N(CC1)CCN1c1ccnc2c1c(OCCO)n[nH]2)=O)c(cc1)ccc1Cl Chemical compound CC(C)NC[C@@H](C(N(CC1)CCN1c1ccnc2c1c(OCCO)n[nH]2)=O)c(cc1)ccc1Cl HUYJXXMOMIZURM-LJQANCHMSA-N 0.000 description 1
- PORMJORUFSXADA-OAQYLSRUSA-N COc1n[nH]c(nc2)c1c(N(CC1)CCN1C([C@@H](Cc(cc1)ccc1Cl)N)=O)c2-c1ccccc1 Chemical compound COc1n[nH]c(nc2)c1c(N(CC1)CCN1C([C@@H](Cc(cc1)ccc1Cl)N)=O)c2-c1ccccc1 PORMJORUFSXADA-OAQYLSRUSA-N 0.000 description 1
- WMBVNAHBGYIBMM-MRXNPFEDSA-N N[C@H](Cc(cc1)ccc1Cl)C(N(CC1)CCN1c(c(cn[nH]1)c1nc1)c1Br)=O Chemical compound N[C@H](Cc(cc1)ccc1Cl)C(N(CC1)CCN1c(c(cn[nH]1)c1nc1)c1Br)=O WMBVNAHBGYIBMM-MRXNPFEDSA-N 0.000 description 1
- CJKNZMSCRYFSAL-ZYMOGRSISA-N N[C@H](Cc(cc1)ccc1Cl)C(N(CC1)CCN1c1ccnc2c1c(OCC(CO)O)n[nH]2)=O Chemical compound N[C@H](Cc(cc1)ccc1Cl)C(N(CC1)CCN1c1ccnc2c1c(OCC(CO)O)n[nH]2)=O CJKNZMSCRYFSAL-ZYMOGRSISA-N 0.000 description 1
- PNASZRMIPBMOOH-DQEYMECFSA-N O=C([C@H]([C@H]1NCCC1)c(cc1)ccc1Cl)N(CC1)CCN1c(c(cn[nH]1)c1nc1)c1-c1ccccc1 Chemical compound O=C([C@H]([C@H]1NCCC1)c(cc1)ccc1Cl)N(CC1)CCN1c(c(cn[nH]1)c1nc1)c1-c1ccccc1 PNASZRMIPBMOOH-DQEYMECFSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1986508P | 2008-01-09 | 2008-01-09 | |
| US61/019,865 | 2008-01-09 | ||
| PCT/US2009/030450 WO2009089359A1 (en) | 2008-01-09 | 2009-01-08 | Pyrazolopyridines as kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014032869A Division JP2014129379A (ja) | 2008-01-09 | 2014-02-24 | キナーゼ阻害薬としてのピラゾロピリジン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011509302A JP2011509302A (ja) | 2011-03-24 |
| JP2011509302A5 true JP2011509302A5 (enExample) | 2012-02-16 |
| JP5608098B2 JP5608098B2 (ja) | 2014-10-15 |
Family
ID=40351716
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010542343A Expired - Fee Related JP5608098B2 (ja) | 2008-01-09 | 2009-01-08 | キナーゼ阻害薬としてのピラゾロピリジン |
| JP2014032869A Withdrawn JP2014129379A (ja) | 2008-01-09 | 2014-02-24 | キナーゼ阻害薬としてのピラゾロピリジン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014032869A Withdrawn JP2014129379A (ja) | 2008-01-09 | 2014-02-24 | キナーゼ阻害薬としてのピラゾロピリジン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8372842B2 (enExample) |
| EP (1) | EP2242757B1 (enExample) |
| JP (2) | JP5608098B2 (enExample) |
| CN (1) | CN101965347B (enExample) |
| CA (1) | CA2711741A1 (enExample) |
| ES (1) | ES2392014T3 (enExample) |
| WO (1) | WO2009089359A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009089352A1 (en) | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| CN108721284A (zh) | 2010-11-16 | 2018-11-02 | 阵列生物制药公司 | 检测点激酶1抑制剂和wee1激酶抑制剂的组合 |
| MX352181B (es) * | 2012-02-02 | 2017-11-13 | Idorsia Pharmaceuticals Ltd | Compuestos 4- (benzoimidazol-2-il) -tiazol y derivados aza relacionados. |
| RU2635359C2 (ru) | 2012-04-23 | 2017-11-13 | Дженентек Инк. | Промежуточные химические соединения и способы получения соединений |
| CN104119331B (zh) * | 2013-04-26 | 2018-02-06 | 广东东阳光药业有限公司 | 烯基化合物及其使用方法和用途 |
| AU2014293013A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| CA2921956C (en) | 2013-08-22 | 2021-10-19 | Genentech, Inc. | Process for preparing (r)-5-bromo-4-(3-amino)piperidin-1-yl)-3-(cyclopropanecarboxamido)-1h-pyrrolo[2,3-b]pyridine |
| GB201410815D0 (en) * | 2014-06-17 | 2014-07-30 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven | Therapeutic agents |
| WO2024209363A1 (en) | 2023-04-06 | 2024-10-10 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69943144D1 (de) | 1998-03-31 | 2011-03-03 | Kyowa Hakko Kirin Co Ltd | Stickstoffenthaltende heterocyclische verbindungen |
| DE19853278A1 (de) | 1998-11-19 | 2000-05-25 | Aventis Pharma Gmbh | Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| US6797825B2 (en) * | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
| JP2005534632A (ja) * | 2002-05-10 | 2005-11-17 | ニューロクライン バイオサイエンセズ， インコーポレイテッド | メラノコルチンレセプターリガンドとしての置換ピペラジン |
| US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| EP1663994B1 (en) | 2003-08-05 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels |
| BRPI0414238A (pt) * | 2003-09-09 | 2006-10-31 | Ono Pharmaceutical Co | antagonistas de crf e compostos heterobicìclicos |
| TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| AU2004293026B2 (en) * | 2003-11-21 | 2012-01-19 | Array Biopharma Inc. | AKT protein kinase inhibitors |
| GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| GB0409080D0 (en) | 2004-04-23 | 2004-05-26 | Biofocus Discovery Ltd | Compounds which interact with protein kinases |
| UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| AU2005322085B2 (en) | 2004-12-28 | 2012-07-19 | Exelixis, Inc. | [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| PE20061119A1 (es) | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| BRPI0608659A2 (pt) | 2005-04-06 | 2010-11-30 | Astrazeneca Ab | composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
| JP2008545660A (ja) * | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| US7541367B2 (en) | 2005-05-31 | 2009-06-02 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US20070082900A1 (en) * | 2005-10-06 | 2007-04-12 | Schering Corporation | Methods for inhibiting protein kinases |
| AU2006315436A1 (en) | 2005-11-15 | 2007-05-24 | Vertex Pharmaceuticals Incorporated | Azaindazoles useful as inhibitors of kinases |
| DE102006005179A1 (de) | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Aminoindazolderivate |
| DE102006005180A1 (de) | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Indazol-heteroaryl-derivate |
| US7723330B2 (en) | 2006-03-07 | 2010-05-25 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
| WO2007125321A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| JP2009534454A (ja) * | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| DE602007011628D1 (de) | 2006-07-06 | 2011-02-10 | Array Biopharma Inc | Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren |
| RU2481336C2 (ru) | 2006-07-06 | 2013-05-10 | Эррэй Биофарма Инк. | Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт |
| WO2008006039A1 (en) | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Dihydrothieno pyrimidines as akt protein kinase inhibitors |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| US8618121B2 (en) * | 2007-07-02 | 2013-12-31 | Cancer Research Technology Limited | 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors |
| MX2009014013A (es) | 2007-07-05 | 2010-01-28 | Array Biopharma Inc | Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt. |
| CA2692502C (en) | 2007-07-05 | 2016-03-01 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| WO2009061781A1 (en) | 2007-11-07 | 2009-05-14 | Schering Corporation | Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| WO2009089352A1 (en) * | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| US8835434B2 (en) | 2008-01-09 | 2014-09-16 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| CN104876921A (zh) | 2008-01-09 | 2015-09-02 | 阵列生物制药公司 | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 |
| US8853216B2 (en) | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| US8481557B2 (en) * | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| KR101676062B1 (ko) | 2009-04-11 | 2016-11-14 | 어레이 바이오파마 인크. | Ｄｎａ 손상제를 강화시키기 위한 체크포인트 키나제 1 억제제 |
| CN108721284A (zh) | 2010-11-16 | 2018-11-02 | 阵列生物制药公司 | 检测点激酶1抑制剂和wee1激酶抑制剂的组合 |
-
2009
- 2009-01-08 EP EP09701216A patent/EP2242757B1/en active Active
- 2009-01-08 ES ES09701216T patent/ES2392014T3/es active Active
- 2009-01-08 CN CN2009801083206A patent/CN101965347B/zh not_active Expired - Fee Related
- 2009-01-08 CA CA2711741A patent/CA2711741A1/en not_active Abandoned
- 2009-01-08 WO PCT/US2009/030450 patent/WO2009089359A1/en not_active Ceased
- 2009-01-08 JP JP2010542343A patent/JP5608098B2/ja not_active Expired - Fee Related
- 2009-01-08 US US12/812,448 patent/US8372842B2/en not_active Expired - Fee Related
-
2014
- 2014-02-24 JP JP2014032869A patent/JP2014129379A/ja not_active Withdrawn